Answers are grounded in this paper and cite their sources.
Our results do not support a role of enoxaparin for improving liver fibrosis, portal hypertension or endothelial dysfunction in active disease at advanced stages of cirrhosis. These disease-related factors and the possibility of a limited therapeutic window should be considered in future studies evaluating the use of anticoagulants in cirrhosis.
No takes yet. Share an insight, caveat, or question.
Fortea et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: